Skip to content

Seminar PH4 – Advanced-therapy medicinal products: new competencies in hospital pharmacy

Room:

Hall F2

Facilitator:

Venturini, Francesca

Speakers:

Abstract:


Linked to EAHP Statements:
Section 6: Education and Research
Section 3: Production and compounding

ACPE UAN: 0475-0000-16-019-L04-P. A knowledge based activity.

Abstract

Advanced-therapy medicinal products (ATMPs) are medicines for human use that are based on gene therapy, somatic-cell therapy or tissue engineering. They offer groundbreaking new opportunities for the treatment of disease and injury.

With the introduction of EU Regulation 1394/2007 in December 2008, all cell products that are substantially manipulated prior to clinical application have to be regarded as medicines, meaning that hospital pharmacies in Europe are responsible for these products and have to oversee all aspects of their use in the hospital. Furthermore, gene therapy medicinal products are commonly already considered as drugs. A first gene therapy drug is already marketed in Europe. However, the amount of cellular and gene therapy-related research and development continues to grow rapidly, arising to introduce them by far in the current pharmacotherapy during the following years.

Advanced therapies introduce enhanced roles for pharmacists in health-system decisions concerning clinical trials, selection, use, and management in hospitals. These goals are reached using the same principles as those of the medication formulary system in which decisions are based on clinical, ethical, legal, social, quality-of-life, safety and pharmacoeconomic factors that result in optimal patient care and include the active and direct involvement of physicians and other healthcare practitioners. However, hospital pharmacist’s training in these new technologies requires a stepwise process to be familiar with highly complex technical and scientific concepts that provide a complete new knowledge paradigm for most pharmacists.

Teaching goals:
 
• To provide a background on ATMPs from the technical and legislative standpoint;
• To provide insights on the ATMPs currently on the market;
• To define the relevant education needs for hospital pharmacists.
 
Learning objectives

After the seminar, the participants should be able:
• to know the principles of ATMPs production and legislation;
• to identify the relevant educational needs for hospital pharmacists.
 
Keywords: Advanced Therapy, AMTPs, Gene therapy, cell products, GMP, cell therapy, tissue engineering, regulation and role of the HP.
×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.